Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post a post on LinkedIn:
“Updated ESMO Clinical Practice Guideline in epithelial ovarian cancer
The latest Express Update provides two updated treatment algorithms:
- First – line maintenance now includes rucaparib, supported by the ATHENA – MONO trial.
- Recurrent platinum – resistant setting incorporates mirvetuximab soravtansine (MIRV) based on positive MIRASOL results.
These updates reflect a rapidly evolving treatment landscape with expanded, evidence – based options across disease settings.”
Title: ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer
Authors: A. González-Martín, J.A. Ledermann, ESMO Guidelines Committee
Read the article
More posts featuring Giuseppe Caruso